Statins
Previous studies in mice have demonstrated statins reduce CiO. Their effect was tested on 277 adults (546 ears) treated with cisplatin and concurrent radiotherapy for head and neck cancer in an observational study. Of the 6 types of statins tested in this observational study, 44% of patients took atorvastatin. The mixed-effect model analysis showed atorvastatin was significantly associated with reduced cisplatin hearing loss (P ≤ 0.01) (OR = 0.47; 95% CI, 0.30–0.78). No significant correlation was found between high-frequency hearing loss and atorvastatin dose. Adverse effects were not reported (Fernandez et al., 2021).
Table 3. Characteristics of the studies assessing pharmacological interventions.